The new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the company's flagship transdermal cannabidiol product candidate -- Zygel CBD gel, according to a statement.
The patent titled “Treatment of Autism with Cannabidiol” includes claims directed to methods of treating ASD by transdermally administering, via a gel or cream, a therapeutically effective amount of purified CBD.
This patent follows the previously announced issuance of a related patent granted by US Patent and Trademark Office to treat ASD by transdermally administering, via gel or cream, synthetic cannabidiol.
Zynerba said it has completed enrollment in the open-label Phase 2 BRIGHT study evaluating the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with ASD, with 37 patients enrolled.
The efficacy assessments include the Aberrant Behavior Checklist, Parent Rated Anxiety Scale – Autism Spectrum Disorder, Autism Impact Measure, and Clinical Global Impression – Severity and Improvement.
Zynerba, based in Devon, Pennsylvania, expects to report top-line data from this trial in the second quarter of 2020.
The company’s stock recently traded 11% higher to $5.13 a share in pre-market trading in New York.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham